The short version of somatotroph fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-19 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Ruling by decree, the RCC maintained the monarchy's ban on political parties, banned trade unions, and in 1972 outlawed workers' strikes and suspended newspapers. In September 1971, Gaddafi resigned, claiming dissatisfaction with the pace of reform, but returned to his position within a month. In July 1972, amid widespread speculation that Gaddafi had been ousted or jailed by his political opponents, a new 18-man cabinet was formed with only two, Jalloud and Abdel Moneim al-Houni, being military men; the rest were civilian technocrats per Gaddafi's insistence. In February 1973, Gaddafi resigned again, once more returning the next month.
=== De–Di === Christian de Duve FRS (foreign associate) (1917–2013). Belgian cytologist and biochemist at the Université Catholique de Louvain, known for discovering peroxisomes and lysosomes. Nobel Prize for Physiology or Medicine (1974). Foreign Associate Natl. Acad. Sci. USA. Michael W. Deem (PhD 1994). American biochemist and genetic engineer at Rice University, known for work in evolution, immunology, and materials. William DeGrado (b. 1955). American pharmaceutical chemist at UC San Francisco, known for protein design, synthesis of peptidomimetics, and characterizing membrane-active peptides and proteins. Member Natl. Acad. Sci. USA. Max Delbrück FRS (1906–1981). German-American biophysicist at Caltech. Nobel Prize in Physiology or Medicine (1969). Member Natl. Acad. Sci. USA. Hector DeLuca (b. 1930). American biochemist at the University of Wisconsin, known for work on vitamin D. Member Natl. Acad. Sci. USA. Pierre De Meyts (1944–2025). Belgian physician and biochemist at the Université Catholique de Louvain, known for studies of hormone-receptor interaction of peptide hormones and the physiopathogenesis of diabetes. Willey Glover Denis (1879–1929). American biochemist at Tulane University, a pioneer in clinical chemistry and the measurement of protein in biological fluids. Rosa Devés (born 1950), Chilean biochemist, first woman rector of the University of Chile. Richard E. Dickerson (1931–2025), American biochemist, the first to carry out a single-crystal structure analysis of B-DNA. Zacharias Dische (1895–1988).
Muhammad, Naseem; Tsai, Peter S.; Lauback, Ronald G. (1982). "High-Pressure Liquid Chromatography Assay for Dane Salt Potassium (-)-N-(1-Methoxycarbonylpropene-2yl)-p-hydroxyphenylglycine". Journal of Liquid Chromatography. 5 (7): 1349–1355. doi:10.1080/01483918208067593. Lauback, Ronald (1984). "Specific High-Performance Liquid Chromatographic Determination of Ampicillin in Bulks, Injectables, Capsules, and Oral Suspensions by Reverse-Phase Ion-Pair Chromatography". Journal of Liquid Chromatography. 7 (6): 1243–1265. doi:10.1080/01483918408074041. Ron Lauback retired in July 2014 from Hanford Pharmaceuticals, based out of Syracuse, New York. He was Vice President of Science from 2007 to 2014.
== Epidemiology == Cardiac myxomas predominantly appear in females in their 30s to 40s. Myxomas are the most common primary cardiac tumor affecting adults, accounting for one quarter to half of primary cardiac tumors seen in clinical practice.
Sources: en.wikipedia.org
== Science and technology == SST (Menter’s Shear Stress Transport), a model used in fluid dynamics Solid-state Technology deployed in every Solid-state battery Salt spray test, a method of measuring corrosion resistance of materials and surface coatings Sea surface temperature Sea surface topography Serum-separating tube, used in venipuncture Socioemotional selectivity theory, a life-span theory of motivation Solid-state transformer, a type of transformer Somatostatin, a peptide hormone Stainless steel (a symbol for stainless steel on engineering drawings as per Y14.38–2007) Steady state topography, a research methodology in cognitive neuroscience and neuromarketing Super Sound Tracing, a demodulation technique for FM tuners by Sony Total sum of squares, in statistics Small Sugary Treat, a liquid form of Sucrose used in behavioural studies of animals
== Mode of action == When the isopeptag is bound to a target protein, it spontaneously binds its binding partner through an isopeptide bond, an amide bond formed autocatalytically. The reaction is robust and occurs at various temperatures from 4-37 °C, a pH range of 5–8, and in the presence of commonly used detergents. Also, the reaction is independent of the redox state of the environment and can occur equally well in both reducing and oxidizing conditions.
=== Pharmacodynamics === Levomethadone has approximately 50x the potency of the S-(+)-enantiomer as well as greater μ-opioid receptor selectivity. Accordingly, it is about twice as potent as methadone by weight and its effects are virtually identical in comparison. In addition to its activity at the opioid receptors, levomethadone has been found to act as a weak competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor complex and as a potent noncompetitive antagonist of the α3β4 nicotinic acetylcholine (nACh) receptor.
=== Life Peer === Baroness Dame Audrey Caroline Emerton, , Chief Officer, Care in the Community, and Co-Chairman, Medical Board, St. John Ambulance; Chairman, Brighton Health Care NHS Trust. Baron Raj Kumar Bagri, , Chairman, London Metal Exchange, and Chairman, MetDist Ltd. Sir Andrew Lloyd Webber, Composer.
== Medical uses == Spironolactone is used in the treatment of heart failure with reduced ejection fraction (HFrEF), where evidence shows that it reduces the risk of heart failure hospitalisation and mortality when added to standard therapy. Multiple studies show that spironolactone improves left ventricular diastolic function in patients with heart failure with preserved ejection fraction HFpEF, though without benefits in death from any cause or overall hospitalisation. One randomised controlled trial showed a modest reduction in hospitalisation due to heart failure. A secondary analysis of TOPCAT suggested possible benefit in patients with both HFpEF and resistant hypertension, but this has not been confirmed in a prospective trial designed for this subgroup. Spironolactone is an effective fourth-line add-on therapy for lowering blood pressure in resistant hypertension that remains uncontrolled despite an ACE inhibitor or ARB, calcium channel blocker, and diuretic. It is also used to treat edematous conditions such as nephrotic syndrome or ascites in people with liver disease, essential hypertension, low blood levels of potassium, secondary hyperaldosteronism (such as occurs with liver cirrhosis), and Conn's syndrome (primary hyperaldosteronism). The most common use of spironolactone is in the treatment of heart failure. On its own, spironolactone is only a weak diuretic because it primarily targets the distal nephron (collecting tubule), where only small amounts of sodium are reabsorbed, but it can be combined with other diuretics to increase efficacy.
Sources: en.wikipedia.org
At cytoplasmic conditions, where the ADP/ATP ratio is 10 orders of magnitude from equilibrium, the ΔG is around −57 kJ/mol. Along with pH, the free energy change of ATP hydrolysis is also associated with Mg2+ concentration, from ΔG°' = −35.7 kJ/mol at a Mg2+ concentration of zero, to ΔG°' = −31 kJ/mol at [Mg2+] = 5 mM. Higher concentrations of Mg2+ decrease free energy released in the reaction due to binding of Mg2+ ions to negatively charged oxygen atoms of ATP at pH 7.
For asymptotically flat universes, Einstein and others salvage conservation of energy by introducing a specific global gravitational potential energy that cancels out mass-energy changes triggered by spacetime expansion or contraction. This global energy has no well-defined density and cannot technically be applied to a non-asymptotically flat universe; however, for practical purposes this can be finessed, and so by this view, energy is conserved in our universe. Alan Guth stated that the universe might be "the ultimate free lunch", and theorized that, when accounting for gravitational potential energy, the net energy of the Universe is zero.
=== Transforming growth factor beta === Transforming growth factor beta (TGF-β) is a physiological regulator of osteoblast differentiation, and acts as a central component in the coupling of bone formation and its resorption during bone remodeling.
==== England (1920, 1923, 1925, 1935, 1938, 1946) ==== Constance Long arranged for Jung to deliver a seminar in Cornwall in 1920. Another seminar was held in 1923, this one organized by Jung's British protégé Helton Godwin Baynes (known as "Peter") (1882–1943), and another in 1925.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.